Kornimate/medical-research-clean huggingface dataset:
perfusion emergency veinlite transillumination

Conditions: Emergencies; Toxicomania; Hypotension; Obesity; Cachexia; Hypothermia

Summary: when taking care of an emergency patient (emergency reception service: uas and urgent medical assistance service: samu), the installation of a peripheral venous route (vvp) is an important step. the benchmark method is the most widely used technique. this vascular access will allow the necessary therapy to be delivered quickly and efficiently. this can be difficult and sometimes doomed to failure for reasons related both to the patient (venous capital not very visible / felt or limited due to the profile of the patient), or sometimes also for reasons related to the patient. environment (limited lighting, difficult patient access). the only current alternatives lie in the use of a device such as the intra-bone device (iid) or the installation of a central venous line. on the other hand, these alternatives are particularly invasive and / or very algogenic. there are other techniques, which are more affordable and "transportable" outside the hospital. indeed, trans-illumination with a very short training seems to be a particularly interesting alternative. it allows, thanks to leds in contact with the skin, to backlight the superficial veins. it is proposed through this project to evaluate this tool for a category of patients considered "difficult" to infuse, both within hospital and outside hospital. the main objective of the study is to assess the effectiveness of the transillumination device, compared to the absence of such a device, on the placement of a peripheral venous line (pvp) in patients with a difficult vascular approach and managed in the emergency room and whose clinical condition does not require the installation of an intraosseous device. this is a multicenter, prospective, controlled, randomized and open clinical study, according to a cross-over design. the intervention evaluated is the placement of a pvr using the trans-illumination device. the control intervention is the placement of a pvr without this device, according to the reference method, which is the benchmark method. 400 patients presenting to the emergency room will be included in the centers of nancy, toul and pont-à-mousson. depending on their randomization group, nurses will perform peripheral venous insertion by the transillumination method or by the control method.


Eligibility criteria:
inclusion criteria: \>= 18 years old * extrem body mass index * hypotension * toxicomania * limited ponction site * hypotherm patient * dehydrated patient * generalized edema * non-supportive environment exclusion criteria: * parturient / pregnant female / breastfeeding mother * unemancipated minor * adults under legal protection * person under judicial protection, guardianship or curatorship

Keywords: adult peripheral venous approach emergency transillumation
tacs for neuropathic pain management after sci

Conditions: Neuropathic Pain Management

Summary: the overall goal is to investigate the effectiveness of a novel intervention - transcranial alternating current stimulation (tacs) for neuropathic pain management in people after spinal cord injury.


Eligibility criteria:
inclusion/exclusion criteria for sci subjects inclusion criteria: a patient who 1. has neuropathic pain after traumatic spinal cord injury or amputation or brain injury; 2. has chronic pain, \>3 months; 3. is between 18 to 75 years of age; 4. is stable on oral pain medications at least two weeks. patients are allowed to continue their pain medications, i.e., no change in pain medications. note: we plan to begin the study with the spinal cord injury (sci) subject population as a cohort first, then expand to other subject populations exclusion criteria: patients will be excluded if they 1. are currently adjusting oral pain medications for their neuropathic pain; 2. have pain, but not neuropathic, e.g., from inflammation at the incision wound of the residual limb or neuroma; 3. have a pacemaker metal implants or supplemental oxygen; 4. have amputation in their arm(s); 5. fail to have a motor contraction in the arm muscles with tms; 6. are not able to follow commands, or to give consent; 7. have asthma or other pulmonary disease; 8. are not medically stable; 9. have preexisting psychiatric disorders; 10. alcohol or drug abuse.

Keywords: tacs neuropathic pain
cilostazol stroke prevention study for antiplatelet combination

Conditions: Noncardioembolic Cerebral Infarction

Summary: to examine the efficacy and safety of dual antiplatelet therapy (dapt) including cilostazol (pletaal od tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in high-risk patients for stroke


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of noncardioembolic is that developed between 8 and 180 days before the start of the protocol treatment * patients with a responsible lesion identified by mri * patients aged 20 to 85 years old when providing informed consent * patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing informed consent * patients meeting at least one of the following criteria a-c: 1. at least 50% stenosis of a major intracranial artery (to the level of a2, m2, or p2) 2. at least 50% stenosis of an extracranial artery (the common carotid artery，internal carotid artery，vertebral artery，brachiocephalic artery，or subclavian artery) 3. two or more of the following risk factors * aged 65 years or more * diabetes mellitus * hypertension * peripheral arterial disease * chronic kidney disease * history of is (excluding the index is for this study) * history of ischemic heart disease * smoking (only current smokers) * patients considered to be able to visit the study site for ambulatory care throughout the observation period * patients who provided written informed consent exclusion criteria: * patients with emboligenic heart disease * patients taking any anticoagulant agents * patients who cannot undergo mri examination for reasons such as claustrophobia and implanted pacemaker * patients scheduled to undergo any surgery, such as percutaneous angioplasty, stent placement, and bypass grafting, during the study period * patients with a drug-eluting coronary stent implanted within one year * patients with a history of symptomatic non-traumatic intracranial hemorrhage, any other hemorrhagic disease (eg, active peptic ulcer), bleeding predisposition, or blood clotting disorders * patients with a history of hypersensitivity to cilostazol * patients with congestive heart failure or uncontrolled angina pectoris * patients with thrombocytopenia (platelet count ≦ 100,000/mm3) * patients with severe liver or renal dysfunction * women who are pregnant, breast-feeding, or of child-bearing potential * patients with a malignant tumor requiring treatment * patients who are taking aspirin, and meet any of the following criteria: * history of hypersensitivity to aspirin or salicylic acid analogues * current peptic ulcer * aspirin-induced asthma or its history * patients who are taking clopidogrel, and meet the following criterion: ・history of hypersensitivity to clopidogrel * patients who are participating in any other clinical studies * patients considered by the investigator/subinvestigator to be unsuitable for participating in this study

Keywords: noncardioembolic cerebral infarction dual antiplatelet therapy (dapt) cilostazol aspirin clopidogrel
prevalence of osteoporosis in patients who uses inhaled steroids

Conditions: Osteoporosis

Summary: the purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from chronic obstructive pulmonary disease (copd) or asthma disease and uses inhaled steroids.


Eligibility criteria:
inclusion criteria: 1. man at the minimum age of 60 years. 2. diagnosed with chronic obstructive pulmonary disease (copd) or asthma disease. 3. usage of the following corticosteroids at the minimal doses indicated, for at least 3 years: seretide 250/50 mcg symbicort 320/9 mcg 5.no diagnosis of thyroid irregularity 6.no diagnosis/treatment for osteoporosis. exclusion criteria: 1. usage of systemic steroids more than once during the 12 months prior to the study. 2. usage of systemic steroids during the month prior to the study. 3. usage of inhaled steroids in order to treat any other disease except chronic obstructive pulmonary disease (copd) or asthma.
study of pulmonary hypertension in patients with chronic myeloproliferative disorders at sohag university hospital

Conditions: Chronic Myeloproliferative Disorders

Summary: pulmonary hypertension (ph) is a complex condition that may be related to many clinical conditions. it is a serious disorder with a high morbidity and mortality rates. ph is classified into five groups according to clinical characteristics, pathological findings, hemodynamic characteristics and treatment response (galie n, et al., 2016). these five groups include pulmonary arterial hypertension, ph due to left sided heart disease, ph due to lung disease and/or hypoxia, chronic thromboembolic pulmonary hypertension, or other pulmonary arterial obstruction and ph with unclear and/or multifactorial mechanisms (simonneau g, et al., 2013). ph is a major complication of several hematologic disorders including myeloproliferative neoplasms (mpns). mpns are a group of diseases characterized by uncontrolled proliferation of at least one myeloid series due to an abnormal hematopoietic cell clone. there are different types of mpns including polycythemia vera (pv), essential thrombocythemia (et), primary myelofibrosis (pmf) \& chronic myeloid leukemia ( cml). myeloproliferative neoplasms (mpns) are included in group 5 ph (arber da, et al., 2016). this study will analyze the clinical and laboratory data of mpns patients and correlate them with development of ph in these patients aiming to identify parameters that can predict ph in mpns patients and thus, identifying mpns patients at highest risk for ph who require close monitoring \& screening for ph hoping that early detection and management of ph in mpns patients can improve morbidity, prognosis and survival in those patients


Eligibility criteria:
inclusion criteria: * patients over 18 years old. * patients diagnosed with polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia according to the 2016 who classification and attended the outpatient hematology clinic at sohag university hospital. exclusion criteria: * patients less than 18 years old. * patients with pre-existing pulmonary hypertension from any other cause. * patients with left sided heart disease e.g. left sided heart failure, left sided valvular diseases, cardiomyopathies, left ventricular systolic or diastolic dysfunction. * patients with chronic lung disease e.g. copd \& interstitial lung disease. * patients with chronic kidney disease. * patients with connective tissue diseases. * patients with congenital heart diseases.
evaluation of the hypnotic properties of zolpidem-mr 12.5 mg and zolpidem 10 mg marketed product compared to placebo in patients with primary insomnia

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the primary objective is to evaluate the hypnotic efficacy of zolpidem-mr (modified release) 12.5 mg and zolpidem 10 mg marketed product in comparison with placebo in patients with primary insomnia and sleep maintenance difficulties, using polysomnography (psg) recordings and patient sleep questionnaires. the secondary objective is to evaluate the clinical safety and tolerability of zolpidem-mr 12.5 mg and zolpidem 10 mg marketed product in comparison with placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of primary insomnia based on diagnostic and statistical manual of mental disorders (dsm-iv) criteria

Keywords: insomnia
risk of nsaids on anastomotic leak for rectal surgery

Conditions: Anastomotic Leak; Anti-Inflammatory Agents, Non-Steroidal

Summary: conflicting reports of the association between early postoperative non-steroidal anti-inflammatory drugs (nsaids) administration and anastomotic leak (al) after rectal surgery have continued. the definition of al and the exposure of nsaids differ from each other among studies, which may result in the different conclusions. the aim of this retrospective study was to clarify the effect of nsaids on anastomotic leak from new angels.

concerning about the side effects induced by opioids, nonsteroidal anti-inflammatory drugs (nsaids) have gained its popularity in eras protocols. nsaids competitively inhibits the activity of cyclooxygenases (coxs), which are involved in migration of epithelial cell and mucosal restitution, angiogenesis and collagen synthesis during healing. conflicting reports of the association between early postoperative non-steroidal anti-inflammatory drugs (nsaids) administration and anastomotic leak (al) after rectal surgery have continued. notably, the definition of al and the exposure of nsaids (i.e. nsaids administration) differ from each other among the studies, which may result in the different conclusions. in concrete terms, the definition of nsaids administration timing varies from the first day to the first week after surgery, while the al was also defined in multiple ways (timing varies from 14 to 90 days postoperatively, or only leaks with operative intervention included). most previous studies suggested that early and late al are different entities with different risk factors. these interesting evidences indicate reconsidering the effect of nsaids on al is needed. hence, investigators defined the nsaids administration as at least once in the early postoperative period--the day of and the day after surgery (nsaid group), to avoid the inclusion of patients started on nsaids secondary to a complication. at the same time, investigators also classified al into early al (confirmed within 6 days) and late al (over 6 days). moreover, concerning the higher rate of al in rectal surgery than colonic surgery and the trend of minimally invasive surgery, investigators performed the current study, aiming to clarify the association between early postoperative nsaids and anastomotic leak in rectal surgery.

Eligibility criteria:
inclusion criteria: * biopsy-proven adenocarcinoma of the rectum * age over 18 years old * patients underwent non-emergency minimally invasive surgery with a primary anastomosis exclusion criteria: * incomplete medical records * patients with distant metastasis before surgery * patients with multiple primary colorectal carcinomas
medication histories conducted by nurses (rns), pharmacy techs (cphts) & pharmacists (rphs)

Conditions: Medication Reconciliation; Emergency Department

Summary: up to 50% of medication errors and 20% of adverse drug reactions (adrs) in the hospital setting are estimated to be related to communication issues regarding patient medications at various transition points of care from admission to discharge. the joint commission (tjc) requires accurate and complete medication reconciliation occur at each transition point throughout hospitalization. evidence from nqf demonstrates pharmacists (rph) are the most effective medication management team leaders in the implementation of medication management practices and design of medication error reduction strategies; medication reconciliation is one of the five safety objectives pharmacists are recommended to lead. in addition, the massachusetts coalition for the prevention of medical errors states strong evidence supports the use of pharmacy technicians (cpht) in conjunction with pharmacists in completing accurate medication histories. wmc nurses (rn) currently are involved in the medication reconciliation process. in 2009, a medication use evaluation (mue) of medication reconciliation accuracy found a 67% medication error rate on admission determined by comparing the nurse-obtained medication history to the pharmacist-obtained medication history. the number of home medications identified by the pharmacist compared to the nurse was 411 versus 312 (p\<0.0001). the total percentage of medication errors prevented by the pharmacist was 66.2. using the va healthcare failure mode effects analysis - hfmea™ hazard scoring matrix, 3 independent pharmacist reviewers found that 18% of patients interviewed had a score greater than 7, and 3 patients had a score of 12 (major/probable), if the discrepancies would not have been identified and corrected by the pharmacist conducting the admission medication reconciliation audit. the same patients' discharge medication reconciliation and discharge medication lists were retrospectively reviewed for the mue, and the total percentage of patients with medication errors on discharge was 43%.


Eligibility criteria:
inclusion criteria: * patients admitted as inpatients from the emergency department exclusion criteria: * prisoners (because the irb does not have a prisoner representative) * patients not admitted as inpatients through the emergency department * patients admitted more than once during the study period

Keywords: medication reconciliation emergency department nurse pharmacist certified pharmacy technician medication reconciliation: inpatients admitted from the ed
confocal raman spectroscopy: in vivo measurement of physiological skin parameters

Conditions: Dermatologic Disorders; Disorder of Cholesterol Metabolism

Summary: the purpose of this study is to i. determine several skin parameters, for example natural moisturizing factor (nmf) and cholesterol, with raman spectroscopy in vivo and ii. compare the results with the corresponding cholesterol levels measured in venous blood.

in vivo raman experiments will be carried out weekly on voluntary participants using a riverdiagnostics gen2-sca skin composition analyzer (riverdiagnostics, rotterdam, netherlands). all experiments will be carried out on the volar forearm. semi-quantitative concentration profiles for several skin parameters will be determined, for example natural moisturizing factor (nmf) and cholesterol. additionally the total cholesterol level will be detected by venous blood sample analysis. the blood samples will be taken weekly within two weeks, similar to the raman measurements.

Eligibility criteria:
inclusion criteria: * provision of subject informed consent * female or male aged between 18 and 65 years exclusion criteria: * pregnancy * chronic skin conditions

Keywords: skin parameters cholesterol raman spectroscopy
comparing intra-articular betamethasone (diprospan) and triamcinolone acetonide injection in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to compare the efficacy of intra-articular corticosteroid injection between betamethasone (diprospan) and triamcinolone acetonide for treatment of knee osteoarthritis

after being informed about the study and potential risks, all patients giving written informed consent will be chosen for eligibility for the study entry. at day 0 (before intra-articular injection), patients who meet the eligibility criteria will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to betamethasone (diprospan 1 ml) or triamcinolone acetonide (40 mg) single intra-articular injection

Eligibility criteria:
inclusion criteria: 1. symptomatic primary knee osteoarthritis (kellgren-lawrence stage 2 or 3) 2. failed other conservative treatment 3. comply with protocol exclusion criteria: 1. allergy to any of the medications in this protocol (betamethasone, triamcinolone, paracetamol, tramadol) 2. previous fracture or surgical procedure 3. previous intra-articular injection in the past 6 months 4. previous oral symptomatic slow-acting drugs for osteoarthritis (sysadoa) (glucosamine, diacerein) used in the past 6 months 5. current infection in the affected limb 6. uncontrolled diabetes mellitus 7. primary or secondary adrenal insufficiency 8. coagulopathy or current anticoagulant used 9. current steroid used 10. lower extremity weakness

Keywords: intra-articular injections corticosteroids triamcinolone acetonide betamethasone nonoperative management
rheumatoid arthritis patients and porphyromonas gingivalis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is the most frequent joint inflammatory disease inducing joint destruction strongly correlated with anti-citrullinated protein antibodies citrullinated anti-peptide (acpa). precise ra etiology remained unclear with a described association between ra and periodontal disease. the missing link could be a gram-negative anaerobic bacterium called porphyromonas gingivalis (p. gingivalis), which is heavily involved in periodontal disease and able to induce gingival citrullinated protein via an enzyme called peptidyl arginine deiminase (pad). dna of p. gingivalis was detected in synovial tissue and in peripheral blood mononuclear cell. to improve knowledge of p. gingivalis involvement in ra, the investigators will compare its effect on various cell type with comparison with another oral bacteria provatella intermedia.


Eligibility criteria:
inclusion criteria: * age \>18 ans * ra or osteoarthritis with joint surgery planned * informed consent approved and signed exclusion criteria: * pregnancy

Keywords: rheumatoid arthritis porphyromonas gingivalis
transcutaneous auricular vagal nerve stimulation for functional dyspepsia with sleep disturbances: a randomized controlled trial

Conditions: Functional Dyspepsia; Sleep Disturbances

Summary: functional dyspepsia(fd) is most common in functional gastrointestinal disorders whose rick factors include sleep disturbances. the medication treatment for functional dyspepsia with sleep disturbances has disadvantages such as addiction and withdrawal symptoms. transcutaneous auricular vagal nerve stimulation(tavns) is a new therapeutic method to improve dyspepsia and sleep. study on tasns for fd with sleep disturbances has not yet been explored.

functional dyspepsia (fd) is most common in functional gastrointestinal disorders whose risk factors include sleep disturbances. the medication treatment for fd with sleep disturbances has disadvantages such as addiction and withdrawal symptoms. transcutaneous auricular vagal nerve stimulation (tavns) is a new therapeutic method to improve dyspepsia and sleep. the study on tavns for fd with sleep disturbances has not yet been explored.60 participants who have fd and sleep disturbances are recruited from the department of the second affiliated hospital of xi'an jiaotong university. inclusion criteria follows: meeting the rome iv diagnostic criteria of fd; pittsburgh sleep quality index(psqi)\>7; aged 18-65 years old; not taking related drugs in past one month; from march 2022 to june 2023; sign informed consent. all patients were randomly divided into 2 groups and respectively treated with tavns and sham-tavns for four weeks. psqi, nepean dyspepsia index (ndi), electrogastrogram (ecg), nutrient drinking satiety test, hamilton anxiety and depression scale, heart rate variability (hrv) and serum melatonin (mlt) were recorded at baseline and after 4-week treatment. the effect and mechanism of tavns for fd with sleep disturbances were investigated by comparing the indexes before and after treatment of tavns and sham-tavns groups. the study was proved by the medical ethics committee of the second affiliated hospital of xi'an jiaotong university.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of functional bloating/distension with rome iv; 2. pittsburgh sleep quality index(psqi)\>7; 3. aged 18-65 years old； exclusion criteria: 1. have taken drugs that may affect gastrointestinal motility and sleep in the past two week; 2. the history of gastrointestinal surgery; 3. with severe heart, liver and kidney diseases; 5.pregnant and breastfeeding women; 6.skin allergies.

Keywords: transcutaneous auricular vagal nerve stimulation functional dyspepsia sleep disturbances